Propanc Biopharma (PPCB) Accumulated Expenses (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Accumulated Expenses of $703190.0 for Q4 2025, up 15.03% year-over-year from $611318.0 in Q4 2024, and up 1797.8% quarter-over-quarter from $37053.0 in Q3 2025.
Propanc Biopharma (PPCB) Accumulated Expenses (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Accumulated Expenses for 15 consecutive years, with $703190.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 15.03% year-over-year to $703190.0; the TTM figure through Dec 2025 stood at $703190.0 (up 15.03% YoY), while the FY2025 annual figure was $667901.0, up 16597.52% from the prior year.
- Accumulated Expenses rose to $703190.0 in Q4 2025 per PPCB's latest filing, from $37053.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $703190.0 in Q4 2025 and bottomed at $4000.0 in Q2 2024.
- Historically, Accumulated Expenses has averaged $258555.8 across 5 years, with a median of $71062.0 in 2021.
- Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 98.91% — and 2025, when it jumped 16597.52%.
- Propanc Biopharma's Accumulated Expenses stood at $420257.0 in 2021, then surged by 32.33% to $556114.0 in 2022, then slumped by 98.91% to $6034.0 in 2023, then jumped by 10031.22% to $611318.0 in 2024, then advanced by 15.03% to $703190.0 in 2025.
- Business Quant data shows PPCB's Accumulated Expenses at $703190.0 in Q4 2025, $37053.0 in Q3 2025, and $667901.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 703,190.00 |
| Sep 30, 2025 | 37,053.00 |
| Jun 30, 2025 | 667,901.00 |
| Mar 31, 2025 | 9,371.00 |
| Dec 31, 2024 | 611,318.00 |
| Sep 30, 2024 | 7,053.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 11,080.00 |
| Dec 31, 2023 | 6,034.00 |
| Sep 30, 2023 | 7,677.00 |
| Jun 30, 2023 | 22,749.00 |
| Mar 31, 2023 | 579,888.00 |
| Dec 31, 2022 | 556,114.00 |
| Sep 30, 2022 | 448,719.00 |
| Jun 30, 2022 | 25,930.00 |
| Mar 31, 2022 | 486,558.00 |
| Dec 31, 2021 | 420,257.00 |
| Sep 30, 2021 | 58,124.00 |
| Jun 30, 2021 | 84,000.00 |
| Mar 31, 2021 | 424,101.00 |